Publicacións en colaboración con investigadores/as de Dalhousie University (8)

2024

  1. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107

2023

  1. Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network

    Open Forum Infectious Diseases

  2. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

2020

  1. Complicated hospitalization due to influenza: Results from the Global Hospital Influenza Network for the 2017-2018 season

    BMC Infectious Diseases, Vol. 20, Núm. 1

2019

  1. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

    Human Vaccines and Immunotherapeutics, Vol. 15, Núm. 12, pp. 2865-2872

  2. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 74, Núm. 8, pp. 1231-1238

  3. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

    Vaccine, Vol. 37, Núm. 18, pp. 2482-2493

2016

  1. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older

    New England Journal of Medicine, Vol. 375, Núm. 11, pp. 1019-1032